Advisory Board

Dimitris Agrafiotis, PhD, FRSC, is a Director at Arsenal Capital Partners, where he's responsible for shaping the digital, data, and AI strategy for the healthcare franchise. Dr. Agrafiotis' expertise lies at the intersection of digital technology, computational and data science, and life sciences and spans the entire R&D continuum across venture-funded biotech, big pharma, and the services industry. Prior to Arsenal, Dr. Agrafiotis served as Chief Digital Officer for Generate Biomedicines, Vice President of Digital for Worldwide Research, Development and Medical for Pfizer, Chief Information Officer for the Novartis Institutes for Biomedical Research, Chief Data Officer and Head of Technology Products for Covance/LabCorp, and Vice President of Research and Early Development Informatics and IT for Johnson & Johnson (J&J). Prior to J&J, he spent ten years at biotech startup 3-Dimensional Pharmaceuticals, from its founding to its IPO and eventual acquisition by J&J, and three years at Parke-Davis as a Senior Scientist in the Computer-Aided Drug Design group. Dr. Agrafiotis received his BS in chemistry from the University of Patras and PhD in theoretical chemistry from Imperial College London and held postdoctoral fellowships at the University of California at Berkeley and Harvard University, where he worked with Nobel laureate EJ Corey. His work is documented in more than 100 peer-reviewed publications and book chapters and 18 issued US patents, and he’s ranked among the world's 1% most cited scientists. In 2012 he was elected Fellow of the Royal Society of Chemistry for his contributions to chemical and pharmaceutical research, and in 2016 he was named in Computerworld’s Premier 100 Technology Leaders for his technology leadership and innovative approaches to business challenges.

Cosmas Giallourakis is a serial physician-scientist entrepreneur having been on the founding team of eight companies. He currently serves as a Venture Partner at RA Ventures, the company incubation arm of RA Capital. Cosmas brings over a decade of leadership experiences at the interface of basic science, drug development and clinical care. After being an Assistant Professor at Harvard Medical School combining patient care with basic science research in his laboratory, Cosmas joined Takeda Pharmaceuticals where he was the Head of Cell and Gene Therapy for the gastroenterology pre-clinical therapeutic area. Subsequently, as an Entrepreneur in Residence at Third Rock Ventures, he helped build multiple companies including Septerna (GPCR focused; IPO 2024) and Asher Bio (cis targeted biologics; >100M raised) and Trace Neuroscience (ALS focus; 100M Series A 2024). In addition, Cosmas was a founder and founding CEO of a circular RNA company funded by Arch/a16z, which was acquired by Orbital Therapeutics. At RA Ventures, Cosmas has founded multiple companies currently in stealth stealth ranging from cancer biologics to in vivo CAR-T programming, while in some instances taking operational roles such as  interim President/CSO. Cosmas’s academic research has been published in journals such as Cell, Science, and Nature. Cosmas received his BS in Physics from Massachusetts Institute of Technology and his MD from Rutgers-New Jersey Medical School. He completed his residency in internal medicine at Yale-New Haven Hospital and completed his clinical gastroenterology at Massachusetts General Hospital.

George Kollias is Member of the Academy of Athens, Professor of Physiology at the Medical School, UoA, and Research Professor at the BSRC "Alexander Fleming". His lab provided proof of principle preclinical studies that led to the development of anti-TNF therapies for Rheumatoid arthritis. He has pioneered genetic approaches to study the function of cytokine signaling in animal models of human diseases and contributed knowledge on the molecular and cellular mechanisms driving chronic inflammation, autoimmunity and cancer. More recently, the lab made pioneering contributions to uncovering the pivotal role of fibroblasts in pathophysiology, instigating new therapeutic opportunities for chronic inflammatory and fibrotic diseases. His work has received 49K citations and an h-index of 99 (Πηγή: Google Scholar). His laboratory is supported by several competitive grants from national sources and the European Commission, and has been awarded with two (2014, 2022) Advanced Grants from the European Research Council (ERC). GK developed the National Research Infrastructures Infrafrontier.GR/Phenotypos from BSRC Fleming, and the precision Medicine pMedGR from the Medical School of Athens. He also founded Fleming’s spinoff Biomedcode Hellas SA as well as Inolysis, an SME developing therapeutics for fibrosis. He is Member of the European Molecular Biology Organization (EMBO). He was elected and served as President and Director of the Biomedical Sciences Research Center “Alexander Fleming” (2002-2010 & 2016-2020). In 2014, he was awarded the Carol-Nachman Award for Rheumatology. GK is Director of the International Graduate Program in "Molecular Biomedicine" running at the Medical School and BSRC Fleming.

Dimitris Skokos, PhD joined Regeneron in 2008 as Staff Scientist and now serves as Vice President of Cancer Immunology. Dimitris’ team is responsible for developing the next generation of combination immunotherapeutic strategies including the costimulatory bispecific antibodies and other foundational antibody medicines to treat cancer. He holds more than 10 patents and 30 publications and was part of the team that developed the FDA approved treatment for metastatic cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma and advanced Non-Small Cell Lung Cancer, Libtayo. He has had the honor to work with esteem scientists, George D. Yancopoulos and Roy P. Vagelos. Prior to joining Regeneron, Dr Skokos was a post-doctoral fellow at the Rockefeller University, working with Ralph Steinman (Nobel Laureate, 2011) and Michel Nussenzweig. He received his PhD and Master’s degrees in Molecular Immunology from the Pasteur Institute, University Paris 5, Rene Descartes School of Medicine, and his BSc. in Cellular Immunology and Physiology from University Paris, France.